The potential role of ribonucleic acid methylation in the pathological mechanisms of fragile X syndrome

被引:3
|
作者
Chen, Yu-Shan [1 ,2 ]
Dong, Jing [1 ]
Tan, Wei [2 ]
Liu, Hui [1 ,2 ]
Zhang, Si-Ming [1 ,2 ]
Zou, Jia [1 ,2 ]
Chen, Yi-Qi [1 ,2 ]
Bai, Shu-Yuan [1 ,2 ]
Zeng, Yan [1 ,2 ,3 ]
机构
[1] Wuhan Univ Sci & Technol, Brain Sci & Adv Technol Inst, Sch Med, Hubei Prov Key Lab Occupat Hazard Identificat & Co, Wuhan, Peoples R China
[2] Wuhan Univ Sci & Technol, Geriatr Hosp, Wuhan, Peoples R China
[3] Wuhan Univ Sci & Technol, West Huangjiahu Rd, Wuhan 430065, Peoples R China
基金
中国国家自然科学基金;
关键词
Fragile X syndrome; RNA modification; 5-methylcytosine (m 5 C); RNA -binding protein; Synaptic function; N6-methyladenosine(m6A); MENTAL-RETARDATION PROTEIN; MESSENGER-RNA TRANSLATION; NUCLEAR EXPORT; MOUSE MODEL; M(6)A RNA; BINDING; 5-HYDROXYMETHYLCYTOSINE; IDENTIFICATION; NEURONS; RIBONUCLEOPROTEIN;
D O I
10.1016/j.bbr.2023.114586
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Fragile X syndrome (FXS) is a common inherited cause of intellectual disabilities and single-gene cause of autism spectrum disorder (ASD), resulting from the loss of functional fragile X messenger ribonucleoprotein (FMRP), an RNA-binding protein (RBP) encoded by the fragile X messenger ribonucleoprotein 1 (FMR1) gene. Ribonucleic acid (RNA) methylation can lead to developmental diseases, including FXS, through various mechanisms mediated by 5-hydroxymethylcytosine, 5-methylcytosine, N6-methyladenosine, etc. Emerging evidence suggests that modifications of some RNA species have been linked to FXS. However, the underlying pathological mechanism has yet to be elucidated. In this review, we reviewed the implication of RNA modification in FXS and summarized its specific characteristics for facilitating the identification of new therapeutic targets.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] ROLE OF DNA METHYLATION IN X-INACTIVATION AND THE FRAGILE X-SYNDROME
    MIGEON, BR
    AMERICAN JOURNAL OF MEDICAL GENETICS, 1993, 46 (06): : 685 - 686
  • [2] Pathological Plasticity in Fragile X Syndrome
    Martin, Brandon S.
    Huntsman, Molly M.
    NEURAL PLASTICITY, 2012, 2012
  • [3] Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment
    Joseph M. Palumbo
    Brian F. Thomas
    Dejan Budimirovic
    Steven Siegel
    Flora Tassone
    Randi Hagerman
    Christopher Faulk
    Stephen O’Quinn
    Terri Sebree
    Journal of Neurodevelopmental Disorders, 15
  • [4] Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment
    Palumbo, Joseph M. M.
    Thomas, Brian F. F.
    Budimirovic, Dejan
    Siegel, Steven
    Tassone, Flora
    Hagerman, Randi
    Faulk, Christopher
    O'Quinn, Stephen
    Sebree, Terri
    JOURNAL OF NEURODEVELOPMENTAL DISORDERS, 2023, 15 (01)
  • [5] CONCERNING THE ROLE OF X-INACTIVATION AND DNA METHYLATION IN FRAGILE X-SYNDROME
    MIGEON, BR
    AMERICAN JOURNAL OF MEDICAL GENETICS, 1992, 43 (1-2): : 291 - 298
  • [6] Methylation analysis of the fragile X syndrome by PCR
    Das, S
    Kubota, T
    Song, M
    Daniel, R
    Berry-Kravis, EM
    Prior, TW
    Popovich, B
    Rosser, L
    Arinami, T
    Ledbetter, DH
    GENETIC TESTING, 1997, 1 (03): : 151 - 155
  • [7] Molecular mechanisms of fragile X syndrome reveal potential therapeutic approaches
    Warren, ST
    NEUROPSYCHOPHARMACOLOGY, 2005, 30 : S71 - S71
  • [8] Mechanisms underlying fragile X syndrome
    Isabel Lokody
    Nature Reviews Genetics, 2014, 15 (4) : 218 - 218
  • [9] Methylation Analysis in Newborn Screening for Fragile X Syndrome
    Godler, David E.
    Amor, David J.
    Slater, Howard R.
    JAMA NEUROLOGY, 2014, 71 (06) : 800 - 800
  • [10] Role of replication and CpG methylation in fragile X syndrome CGG deletions in primate cells
    Edamura, KN
    Leonard, MR
    Pearson, CE
    AMERICAN JOURNAL OF HUMAN GENETICS, 2005, 76 (02) : 302 - 311